Numerous clinical trials evaluate losartan potassium across diverse therapeutic areas, including essential arterial hypertension, macroalbuminuric diabetic nephropathy, radiation-induced pulmonary fibrosis, triple-negative breast cancer, schizophrenia, and major depressive disorder. Spanning early to late clinical phases, these studies receive support from academic health centers and research sponsors such as the National Cancer Institute. Protocols reflect varied recruitment statuses, including recruiting, active not recruiting, completed, terminated, and withdrawn.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00162474 | RECRUITING | Healthy |
Hadassah Medical Organization |
2003-09 | |
| NCT07762703 | NOT_YET_RECRUITING | Triple-Negative Breast Cancer (TNBC) |
BreakBio Corp |
2026-09 | PHASE1; PHASE2 |
| NCT07762716 | NOT_YET_RECRUITING | Glioblastoma (GBM) |
BreakBio Corp |
2026-09 | PHASE1; PHASE2 |
| NCT06933706 | RECRUITING | Multi-ligament Knee Injury |
Brigham and Women's Hospital |
2025-10-01 | PHASE2 |
| NCT07099859 | RECRUITING | Heart Valve Diseases; Left Ventricle Remodeling; Aortic Regurgitation Disease; Heart Failure Congestive; Natriuretic Peptide, Brain |
Vitor Emer Egypto Rosa |
2025-07-01 | PHASE4 |
| NCT07160361 | NOT_YET_RECRUITING | Carcinoma, Hepatocellular |
Second Affiliated Hospital of Xi'an Jiaotong University |
2025-10-01 | PHASE4 |
| NCT07135687 | NOT_YET_RECRUITING | ACL Injury; ACL Reconstruction; Scar Formation |
Rush University Medical Center |
2026-08 | PHASE4 |
| NCT06150560 | ENROLLING_BY_INVITATION | Coarctation of Aorta; High Blood Pressure |
Mayo Clinic |
2024-04-01 | PHASE3 |
| NCT05331144 | ACTIVE_NOT_RECRUITING | Cognitively Normal Older Adults; Hypertension; Subjective Cognitive Decline; Family History of Dementia |
Rong Zhang |
2022-10-25 | PHASE2 |
| NCT07568574 | ENROLLING_BY_INVITATION | Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes |
Enhanced Emirates Limited |
2026-03-12 | |
| NCT07265739 | NOT_YET_RECRUITING | Platinum Resistant Ovarian Cancer |
Massachusetts General Hospital |
2026-08 | PHASE2 |
| NCT05637216 | ACTIVE_NOT_RECRUITING | Radiation Induced Fibrosis |
Shaw Cancer Center |
2023-08-17 | PHASE2 |
| NCT03900793 | RECRUITING | Osteosarcoma |
University of Colorado, Denver |
2019-08-26 | PHASE1 |
| NCT06108063 | RECRUITING | Knee Arthroplasty, Total |
Steadman Philippon Research Institute |
2024-03-06 | PHASE1; PHASE2 |
| NCT07748273 | NOT_YET_RECRUITING | Obesity & Overweight; Bariatric Surgery; Pharmacokinetics After Oral Intake; Drug Absorption |
Hospital das Clínicas de Ribeirão Preto |
2026-08-02 | |
| NCT06364176 | RECRUITING | Cystic Fibrosis |
University of Kansas Medical Center |
2024-06-03 | PHASE2 |
| NCT02560805 | RECRUITING | Stress Disorders, Post-Traumatic |
Emory University |
2015-10 | PHASE2 |
| NCT07449000 | RECRUITING | Corneal Scarring Fibrosis |
Universidad Autonoma de Nuevo Leon |
2026-02-12 | |
| NCT07784621 | NOT_YET_RECRUITING | Hypertension |
Huons Co., Ltd. |
2026-10 | PHASE1 |
| NCT07017023 | RECRUITING | Emotional Processing; Mood |
University of Oxford |
2025-07-08 | EARLY_PHASE1 |
| NCT04715568 | RECRUITING | Cardiovascular Diseases; Hypertension |
University of California, San Francisco |
2021-03-30 | PHASE4 |
| NCT05077800 | ACTIVE_NOT_RECRUITING | Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic |
Colin D. Weekes, M.D., PhD |
2022-03-21 | PHASE2 |
| NCT06211335 | RECRUITING | Locally Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma |
University of California, Davis |
2023-12-07 | PHASE1 |
| NCT07513350 | RECRUITING | Adhesive Capsulitis of Shoulder |
Istanbul University |
2026-01-07 | |
| NCT01199978 | ACTIVE_NOT_RECRUITING | Vestibular Schwannoma; Acoustic Neuroma |
Massachusetts General Hospital |
2011-03-08 | PHASE2 |
| NCT03417388 | ACTIVE_NOT_RECRUITING | Coronary Artery Disease |
Cedars-Sinai Medical Center |
2018-02-09 | PHASE4 |
| NCT06539806 | UNKNOWN | Pancreatic Cancer |
Tanta University |
2024-07-20 | |
| NCT07683585 | RECRUITING | Hypertension; Coronary Arterial Disease; Percutaneous Coronary Intervention |
National Medical Research Center for Therapy and Preventive Medicine |
2026-04-01 | |
| NCT07300670 | RECRUITING | Possible Interaction Between Losartan and Cephalexin; Healthy |
Aleksi Tornio |
2026-03-04 | PHASE1 |
| NCT05370599 | TERMINATED | Hypertension |
University of California, San Francisco |
2022-04-15 | PHASE2 |
| NCT06333522 | WITHDRAWN | Arthrofibrosis of Knee |
NYU Langone Health |
2024-07-01 | PHASE4 |
| NCT06636812 | RECRUITING | Emotional Processing |
University of Oxford |
2024-03-07 | EARLY_PHASE1 |
| NCT05365893 | ACTIVE_NOT_RECRUITING | Pancreatic Ductal Adenocarcinoma |
Fox Chase Cancer Center |
2021-10-20 | EARLY_PHASE1 |
| NCT06431477 | UNKNOWN | Diabetic Nephropathies; Hypertension |
Chong Kun Dang Pharmaceutical |
2023-04-19 | PHASE4 |
| NCT05607017 | COMPLETED | Breast Cancer; Myocardial Fibrosis; Radiation-Induced Fibrosis |
Massachusetts General Hospital |
2023-09-13 | EARLY_PHASE1 |
| NCT05012631 | COMPLETED | Sickle Cell Disease; Diffuse Myocardial Fibrosis |
Children's Hospital Medical Center, Cincinnati |
2021-09-01 | PHASE2 |
| NCT06624904 | RECRUITING | Social Cognition |
University of Oxford |
2024-08-19 | EARLY_PHASE1 |
| NCT03435939 | COMPLETED | Cystic Fibrosis |
University of Kansas Medical Center |
2022-02-15 | EARLY_PHASE1 |
| NCT06344247 | UNKNOWN | Obesity; Chronic Kidney Diseases |
RenJi Hospital |
2023-09-01 | |
| NCT05619653 | ACTIVE_NOT_RECRUITING | COVID-19 Associated Cardiac Involvement; Remodeling, Left Ventricle; Remodeling, Vascular; Left Ventricular Dysfunction; Exercise Intolerance; Vascular Inflammation; Microvascular Angina; Long COVID; Myocarditis, Pericarditis |
Valentina Puentmann |
2022-12-12 | PHASE3 |
| NCT06491940 | UNKNOWN | Proteinuria |
RESnTEC, Institute of Research |
2024-08-01 | |
| NCT06628154 | RECRUITING | Emotional Processing |
University of Oxford |
2024-08-14 | EARLY_PHASE1 |
| NCT06329050 | UNKNOWN | Healthy |
University of Electronic Science and Technology of China |
2024-03-05 | |
| NCT06329076 | UNKNOWN | Healthy |
University of Electronic Science and Technology of China |
2024-03-05 | |
| NCT06135493 | COMPLETED | Peripheral Neuropathy Due to Chemotherapy |
Future University in Egypt |
2023-12-12 | PHASE2 |
| NCT04815902 | UNKNOWN | Osteoarthritis, Knee |
Steadman Philippon Research Institute |
2021-05-18 | PHASE1; PHASE2 |
| NCT05157464 | WITHDRAWN | Arthrofibrosis |
NYU Langone Health |
2023-09-01 | PHASE4 |
| NCT05861336 | WITHDRAWN | Pancreatic Cancer |
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
2023-06-14 | PHASE2 |
| NCT04539808 | ACTIVE_NOT_RECRUITING | Pancreatic Adenocarcinoma; Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8; Stage I Pancreatic Cancer American Joint Committee on Cancer v8; Stage III Pancreatic Cancer American Joint Committee on Cancer v8; Stage IV Pancreatic Cancer American Joint Committee on Cancer v8 |
OHSU Knight Cancer Institute |
2021-05-27 | PHASE2 |
| NCT04106856 | COMPLETED | Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Locally Advanced Unresectable Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8 |
University of Utah |
2019-08-08 | PHASE1 |
| NCT05025956 | UNKNOWN | Femoroacetabular Impingement |
Steadman Philippon Research Institute |
2021-10-24 | PHASE1; PHASE2 |
| NCT05753696 | UNKNOWN | Proteinuria; Kidney Dysfunction; Blood Pressure; Diabetic Kidney Disease |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-04-01 | |
| NCT03951142 | UNKNOWN | Glioblastoma; Brain Metastases |
Kyrre Eeg Emblem |
2019-10-01 | PHASE2 |
| NCT05097248 | UNKNOWN | Breast Cancer |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2021-10 | PHASE2 |
| NCT05893108 | UNKNOWN | Keloid |
Yuni Eka Anggraini |
2024-03-30 | PHASE1; PHASE2 |
| NCT03295734 | COMPLETED | Hypertension; Aging; Sedentary Lifestyle |
University of Alabama at Birmingham |
2018-05-29 | PHASE2 |
| NCT02246257 | UNKNOWN | Rheumatoid Arthritis; Cardiovascular Diseases |
MD, PhD, Annemarie Lyng Svensson |
2014-09 | |
| NCT03946514 | COMPLETED | Hypertension |
Shanghai Jiao Tong University School of Medicine |
2018-09-01 | PHASE4 |
| NCT04632589 | COMPLETED | Preeclampsia Postpartum |
Anna Stanhewicz, PhD |
2020-11-22 | EARLY_PHASE1 |
| NCT05871333 | UNKNOWN | Chemotherapy; Colorectal Cancer; Intestinal Mucositis; Oral Mucositis |
Ain Shams University |
2023-07-17 | PHASE2 |
| NCT05271448 | UNKNOWN | Contrast-induced Nephropathy; Chronic Kidney Diseases; Ischemic Heart Disease |
An-Najah National University |
2021-06-01 | |
| NCT06718062 | COMPLETED | Hypertension,Essential; Hyperuricemia |
Hansung University |
2021-05-01 | PHASE4 |
| NCT05402397 | COMPLETED | Uric Acid Nephropathy |
Hospital General de Niños Pedro de Elizalde |
2022-07-01 | PHASE4 |
| NCT05843162 | UNKNOWN | Essential Hypertension; Metabolic Syndrome |
Chong Kun Dang Pharmaceutical |
2023-06-01 | PHASE4 |
| NCT05212597 | UNKNOWN | Aortic Valve Insufficiency |
Samsung Medical Center |
2022-01-12 | PHASE2 |
| NCT04927299 | COMPLETED | Essential Arterial Hypertension |
Laboratorios Silanes S.A. de C.V. |
2022-06-30 | PHASE3 |
| NCT01620788 | SUSPENDED | Hypertension |
EMS |
2019-11-27 | PHASE3 |
| NCT03603938 | UNKNOWN | Chronic Kidney Disease Patients |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2018-11-01 | |
| NCT03692013 | UNKNOWN | Hypertension,Nephropathy |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2018-12-01 | PHASE4 |
| NCT03632213 | UNKNOWN | Mucopolysaccharidosis IV A; Mucopolysaccharidosis VI; Mucopolysaccharidoses; MPS IV A; MPS VI; MPS - Mucopolysaccharidosis; Morquio A Syndrome; Morquio Syndrome A; Morquio Syndrome |
Hospital de Clinicas de Porto Alegre |
2018-11-07 | PHASE2 |
| NCT05576155 | COMPLETED | Sex Differences |
Anna Stanhewicz, PhD |
2022-10-03 | EARLY_PHASE1 |
| NCT02263729 | TERMINATED | Hamstring Injury |
James J. Irrgang |
2016-08-10 | PHASE1; PHASE2 |
| NCT05132712 | UNKNOWN | Vascular Access Complication |
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi |
2021-10-01 | EARLY_PHASE1 |
| NCT03082014 | TERMINATED | Cerebral Small Vessel Diseases |
Ludwig-Maximilians - University of Munich |
2018-02-22 | PHASE3 |
| NCT03666351 | COMPLETED | Aortic Stenosis; Aortic Regurgitation; Hypertension; LVM; Left Ventricular Hypertrophy |
Hanmi Pharmaceutical Company Limited |
2018-10-18 | PHASE4 |
| NCT03864042 | COMPLETED | Advanced Solid Tumors; Metastatic Melanoma |
Pfizer |
2018-01-02 | PHASE1 |
| NCT04447235 | TERMINATED | Cancer; COVID; Coronavirus Infection |
Instituto do Cancer do Estado de São Paulo |
2020-07-23 | PHASE2 |
| NCT05713396 | COMPLETED | Diabetes Mellitus |
AHEPA University Hospital |
2017-01-01 | PHASE4 |
| NCT04504045 | TERMINATED | Diabetes Mellitus, Type 2 |
University of Southern Denmark |
2020-09-01 | PHASE1 |
| NCT04606563 | TERMINATED | Covid19; SARS-CoV Infection |
University of British Columbia |
2020-10-09 | PHASE3 |
| NCT05828940 | COMPLETED | PTSD |
University of Oxford |
2019-10-01 | |
| NCT03563248 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer |
Massachusetts General Hospital |
2018-08-10 | PHASE2 |
| NCT01854814 | COMPLETED | IgA Nephropathy |
Fan Fan Hou |
2013-07 | |
| NCT05232370 | COMPLETED | Oxidative Stress |
Unidad de Investigacion Medica en Enfermedades Renales |
2022-01-01 | PHASE2 |
| NCT04604938 | UNKNOWN | Healthy |
University of Electronic Science and Technology of China |
2020-10-10 | |
| NCT04604756 | UNKNOWN | Healthy |
University of Electronic Science and Technology of China |
2020-10-10 | |
| NCT03357653 | UNKNOWN | Glomerulonephritis, Immunoglobulin A (IgA) |
Ewha Womans University |
2018-01-30 | PHASE3 |
| NCT04606212 | UNKNOWN | Healthy |
University of Electronic Science and Technology of China |
2020-10-10 | |
| NCT04606225 | UNKNOWN | Healthy |
University of Electronic Science and Technology of China |
2020-10-10 | |
| NCT04643691 | TERMINATED | COVID-19; ARDS |
Assistance Publique Hopitaux De Marseille |
2020-09-11 | PHASE2 |
| NCT02913664 | COMPLETED | Cognitively Normal Older Adults; Hypertension; Subjective Cognitive Decline; Family History of Alzheimer's Disease |
University of Texas Southwestern Medical Center |
2017-02-02 | PHASE2; PHASE3 |
| NCT04238702 | COMPLETED | Diabetes Mellitus, Type 2; Diabetic Kidney Disease |
Amsterdam UMC, location VUmc |
2020-11-04 | PHASE4 |
| NCT04328012 | TERMINATED | SARS-CoV-2 Infection |
Bassett Healthcare |
2020-04-06 | PHASE2; PHASE3 |
| NCT03604003 | UNKNOWN | Chronic Kidney Disease |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2018-11-30 | |
| NCT04078711 | UNKNOWN | Hypertension; Renal Injury |
Jiangsu Province Hospital of Traditional Chinese Medicine |
2019-09-10 | PHASE2; PHASE3 |
| NCT02769130 | SUSPENDED | Pulmonary Vein Stenosis; Children |
The Hospital for Sick Children |
2016-05 | PHASE1; PHASE2 |
| NCT04343001 | WITHDRAWN | Covid-19 |
London School of Hygiene and Tropical Medicine |
2020-10 | PHASE3 |
| NCT02696564 | COMPLETED | Emphysema |
JHSPH Center for Clinical Trials |
2017-05-23 | PHASE4 |
| NCT04311177 | COMPLETED | Corona Virus Infection; Acute Respiratory Distress Syndrome; SARS-CoV Infection |
University of Minnesota |
2020-04-09 | PHASE2 |
| NCT04312009 | COMPLETED | Corona Virus Infection; Acute Respiratory Distress Syndrome; SARS-CoV Infection |
University of Minnesota |
2020-04-13 | PHASE2 |
| NCT02373241 | TERMINATED | Anemia, Sickle Cell; Sickle Cell Disease; Kidney Disease; Hypertension; Proteinuria |
University of Alabama at Birmingham |
2015-04 | PHASE2 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT04212650 | TERMINATED | Hip Osteoarthritis; Hip Impingement Syndrome; Cartilage Damage; Fibrosis |
Steadman Philippon Research Institute |
2020-08-07 | PHASE1; PHASE2 |
| NCT03461003 | COMPLETED | Pediatric Hypertension |
The University of Texas Health Science Center, Houston |
2018-04-02 | PHASE4 |
| NCT02188121 | COMPLETED | Serious Mental Illness; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Cardiovascular Disease; Major Depressive Disorder; Psychosis NOS |
Mclean Hospital |
2015-02 | PHASE4 |
| NCT04349410 | COMPLETED | CoVid 19 Positive |
The Camelot Foundation |
2020-04-11 | PHASE2; PHASE3 |
| NCT03953950 | UNKNOWN | End Stage Renal Disease; Peritoneal Dialysis |
Chiang Mai University |
2019-10 | PHASE4 |
| NCT02760615 | WITHDRAWN | Colitis, Ulcerative; Crohn Disease |
Takeda |
2016-11-01 | PHASE4 |
| NCT03467217 | TERMINATED | NAFLD - Nonalcoholic Fatty Liver Disease |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2018-10-02 | PHASE2 |
| NCT03147092 | UNKNOWN | Hypertension; Blood Pressure |
Centro Neurológico de Pesquisa e Reabiitação, Brazil |
2018-02-01 | EARLY_PHASE1 |
| NCT04335123 | COMPLETED | COVID-19 |
University of Kansas Medical Center |
2020-04-04 | PHASE1 |
| NCT04340557 | COMPLETED | SARS-CoV Infection |
Sharp HealthCare |
2020-03-27 | PHASE4 |
| NCT04428268 | WITHDRAWN | COVID-19 Pneumonia |
Hospital Universitario Dr. Jose E. Gonzalez |
2020-03-10 | PHASE2 |
| NCT03978884 | WITHDRAWN | Diabetes Mellitus; Hypertension |
The University of The West Indies |
2019-06-01 | PHASE4 |
| NCT05090449 | COMPLETED | Healthy |
Laboratorios Silanes S.A. de C.V. |
2019-05-01 | PHASE1 |
| NCT04074551 | COMPLETED | Hypertension; Dyslipidemias |
Hanmi Pharmaceutical Company Limited |
2019-07-16 | PHASE3 |
| NCT02709018 | COMPLETED | Posttraumatic Stress Disorder |
University of California, San Diego |
2016-07-16 | |
| NCT03897868 | COMPLETED | Hypertension |
Hanmi Pharmaceutical Company Limited |
2019-03-21 | PHASE2 |
| NCT03371823 | TERMINATED | Cardiovascular Diseases; Hypertension |
University of Delaware |
2017-09-01 | PHASE4 |
| NCT02620306 | COMPLETED | Chronic Kidney Disease |
Boryung Pharmaceutical Co., Ltd |
2016-02-11 | PHASE3 |
| NCT02235909 | COMPLETED | Hypertension |
Arbor Pharmaceuticals, Inc. |
2015-03-30 | PHASE3 |
| NCT03206788 | TERMINATED | Cystic Fibrosis |
University of Miami |
2017-11-11 | PHASE2 |
| NCT03578042 | UNKNOWN | Hypertension |
Hotel Dieu de France Hospital |
2017-04-01 | PHASE4 |
| NCT02768948 | COMPLETED | Diabetic Nephropathy |
Centre Hospitalier Universitaire de Nice |
2017-05-05 | |
| NCT03335904 | COMPLETED | Sleep Disordered Breathing; Hypoxia; Respiration; Sleep Disorder; Chemoreceptor Apnea |
University of British Columbia |
2018-01-01 | PHASE4 |
| NCT03526042 | UNKNOWN | Atherosclerosis; Lupus Nephritis |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2017-09-10 | |
| NCT03029091 | COMPLETED | Eosinophilic Esophagitis |
Children's Hospital Medical Center, Cincinnati |
2017-05-23 | PHASE2 |
| NCT01852942 | COMPLETED | HIV Infection; HIV Infections |
University of Minnesota |
2014-09 | PHASE2 |
| NCT01276613 | TERMINATED | Pancreatic Cancer |
M.D. Anderson Cancer Center |
2011-01 | EARLY_PHASE1 |
| NCT03626259 | UNKNOWN | Hypertension |
Centro Universitario de Ciencias de la Salud, Mexico |
2018-08-06 | PHASE4 |
| NCT02049307 | COMPLETED | Inflammation; Fibrosis |
Hennepin Healthcare Research Institute |
2014-10-16 | PHASE2 |
| NCT04278495 | COMPLETED | Losartan Adverse Reaction; Uropathy; Uropathy Obstructive |
Mansoura University |
2014-09-01 | |
| NCT03505853 | COMPLETED | Acute Intermittent Porphyria (AIP); Acute Hepatic Porphyria (AHP); Porphyria, Acute Intermittent; Acute Porphyria |
Alnylam Pharmaceuticals |
2018-04-26 | PHASE1 |
| NCT03396523 | UNKNOWN | Healthy |
University of Electronic Science and Technology of China |
2018-01-04 | |
| NCT03763409 | COMPLETED | Memory; Learning |
University of Oxford |
2018-03-01 | |
| NCT02278471 | COMPLETED | Hypertension; Hyperlipidemia |
Vanderbilt University |
2015-12 | PHASE2 |
| NCT02676466 | COMPLETED | Inflammation |
University of Florida |
2016-04-26 | PHASE2 |
| NCT03459911 | COMPLETED | Healthy |
Pharmtechnology LLC |
2018-02-16 | PHASE1 |
| NCT04222686 | COMPLETED | Type 2 Diabetes Mellitus |
Yaounde Central Hospital |
2017-12-20 | PHASE4 |
| NCT03217825 | COMPLETED | Hypertension |
Windtree Therapeutics |
2015-12 | PHASE2 |
| NCT01821729 | COMPLETED | Pancreatic Cancer |
Massachusetts General Hospital |
2013-08-16 | PHASE2 |
| NCT02010905 | UNKNOWN | Tetralogy of Fallot; Heart Defects, Congenital; Ventricular Dysfunction, Right |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2013-12 | PHASE2 |
| NCT01198496 | UNKNOWN | Hypertension; Stroke; Blood Pressure |
Biomedis International Ltd. |
2010-10 | PHASE4 |
| NCT05827484 | COMPLETED | PRP; Losartan; Muscle Injury; Sport Injury |
Mostafa Hassanein, Msc |
2016-10-10 | PHASE4 |
| NCT02744456 | COMPLETED | Hypertension; High Blood Pressure |
Columbia University |
2014-08-01 | EARLY_PHASE1 |
| NCT02900729 | UNKNOWN | Hypertension |
Shanghai WiseGain Medical Devices Co., Ltd. |
2016-10 | PHASE3 |
| NCT03434054 | COMPLETED | Healthy Volunteers |
University of Oxford |
2016-06-01 | |
| NCT02521246 | WITHDRAWN | Essential Arterial Hypertension |
EMS |
2016-11 | PHASE3 |
| NCT02521233 | WITHDRAWN | Essential Arterial Hypertension |
EMS |
2016-11 | PHASE3 |
| NCT02416102 | TERMINATED | COPD; Chronic Bronchitis |
University of Miami |
2016-03-31 | PHASE4 |
| NCT01964079 | COMPLETED | Hypertension |
Wonju Severance Christian Hospital |
2013-04 | PHASE4 |
| NCT01292694 | TERMINATED | Hypertension; Pure Autonomic Failure; Multiple System Atrophy |
Vanderbilt University |
2011-03 | PHASE1 |
| NCT02704494 | COMPLETED | Diabetic Nephropathy |
Shiraz University of Medical Sciences |
2016-03 | EARLY_PHASE1 |
| NCT00223717 | COMPLETED | Hypertension |
Vanderbilt University |
2001-01 | PHASE1 |
| NCT04049734 | COMPLETED | Post-ERCP Acute Pancreatitis |
Ain Shams University |
2015-01 | PHASE1 |
| NCT01989078 | COMPLETED | Sickle Cell Disease |
Emory University |
2012-12 | EARLY_PHASE1 |
| NCT02232776 | COMPLETED | Glomerulonephritis, IGA |
Seoul National University Hospital |
2014-10 | PHASE3 |
| NCT00981747 | TERMINATED | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis |
Alicia Gerke |
2009-09 | PHASE2; PHASE3 |
| NCT02958631 | UNKNOWN | Hypertension |
Chuncheon Sacred Heart Hospital |
2014-11 | PHASE4 |
| NCT01989793 | COMPLETED | Sarcopenia |
Johns Hopkins University |
2013-07 | PHASE2 |
| NCT02231125 | UNKNOWN | IgA Nephropathy |
Chen Xiangmei |
2014-09 | PHASE4 |
| NCT02232763 | COMPLETED | Proteinuria |
Seoul National University Hospital |
2014-09 | PHASE3 |
| NCT02663141 | COMPLETED | Diabetic Macular Edema |
Tehran University of Medical Sciences |
2015-06 | PHASE2 |
| NCT02294539 | COMPLETED | Hypertension |
Chong-Jin Kim |
2014-08 | PHASE4 |
| NCT01845688 | COMPLETED | Idiopathic Membranous Nephropathy |
wanglin |
2011-11 | |
| NCT02190318 | UNKNOWN | Chronic Renal Disease |
Second Xiangya Hospital of Central South University |
2013-11 | |
| NCT01913470 | COMPLETED | NAFLD |
Miriam Vos, MD |
2013-07 | PHASE2 |
| NCT01479439 | COMPLETED | Nephropathy; Sickle Cell Anemia |
Children's Hospital Medical Center, Cincinnati |
2012-02 | PHASE2 |
| NCT02410005 | TERMINATED | Diabetic Nephropathies |
Weill Cornell Medical College in Qatar |
2014-10 | PHASE2; PHASE3 |
| NCT02121041 | COMPLETED | Hypertension |
Anthony J Viera, MD, MPH |
2014-05 | |
| NCT03006952 | COMPLETED | Diabetic Nephropathies |
Tehran University of Medical Sciences |
2015-04 | PHASE4 |
| NCT02248961 | COMPLETED | Arterial Hypertension |
R-Pharm |
2014-05 | PHASE3 |
| NCT02063100 | UNKNOWN | Glomerulonephritis; Proteinuria |
Chinese PLA General Hospital |
2014-02 | PHASE4 |
| NCT01210430 | COMPLETED | Postural Tachycardia Syndrome |
New York Medical College |
2010-07 | EARLY_PHASE1 |
| NCT01637623 | COMPLETED | Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour); Hypertension |
University of Wisconsin, Madison |
2012-06 | PHASE2 |
| NCT01384591 | COMPLETED | Aging |
The University of Texas Medical Branch, Galveston |
2011-07 | PHASE1; PHASE2 |
| NCT01805453 | COMPLETED | Newly-diagnosed Glioblastoma |
Assistance Publique - Hôpitaux de Paris |
2013-03-29 | PHASE3 |
| NCT01808196 | COMPLETED | Eosinophilic Esophagitis; Connective Tissue Disorders |
Children's Hospital Medical Center, Cincinnati |
2013-10-10 | PHASE2 |
| NCT01603940 | COMPLETED | Hypertension; Diabetes Mellitus |
Hospital Universitario Pedro Ernesto |
2012-05 | PHASE4 |
| NCT02212769 | COMPLETED | Healthy |
Dong Wha Pharmaceutical Co. Ltd. |
2014-08 | PHASE1 |
| NCT00994617 | UNKNOWN | Hypertension, Resistant to Conventional Therapy; Essential Hypertension |
University of Cambridge |
2010-01 | PHASE4 |
| NCT00782327 | COMPLETED | Marfan Syndrome |
University Hospital, Ghent |
2009-11-01 | PHASE3 |
| NCT01051219 | COMPLETED | Nonalcoholic Steatohepatitis |
Newcastle-upon-Tyne Hospitals NHS Trust |
2011-05 | PHASE3 |
| NCT01541943 | COMPLETED | Essential Hypertension; Hyperlipidemia |
HanAll BioPharma Co., Ltd. |
2012-03 | PHASE3 |
| NCT00971165 | COMPLETED | Hypertension; Cardiovascular Disease |
Hospital de Clinicas de Porto Alegre |
2010-07 | PHASE3 |
| NCT00555217 | TERMINATED | Kidney Disease; Nephropathy; Type 2 Diabetes |
US Department of Veterans Affairs |
2008-07 | PHASE3 |
| NCT01675362 | COMPLETED | Kidney Calculi |
Mansoura University |
2012-08 | PHASE4 |
| NCT01150201 | COMPLETED | Kidney Disease |
The University of Hong Kong |
2009-07 | PHASE4 |
| NCT00602004 | COMPLETED | Renal Failure; Left Ventricular Hypertrophy |
Melbourne Health |
2006-10 | |
| NCT00720226 | COMPLETED | COPD; Emphysema; Chronic Bronchitis; Smoking |
Johns Hopkins University |
2008-07 | PHASE4 |
| NCT01447654 | COMPLETED | Hypertrophic Cardiomyopathy |
Henning Bundgaard |
2011-11 | PHASE2 |
| NCT00805311 | TERMINATED | Carotid Artery Stenosis; Atherosclerosis; Stroke |
Russian Cardiology Research and Production Center |
2009-04 | PHASE4 |
| NCT02140489 | UNKNOWN | Healthy |
Hanmi Pharmaceutical Company Limited |
2014-02 | PHASE1 |
| NCT02446548 | COMPLETED | Albuminuria |
Medical University of Gdansk |
2013-03 | |
| NCT01766505 | TERMINATED | Hypertension |
Chong Kun Dang Pharmaceutical |
2012-06 | PHASE4 |
| NCT00630708 | TERMINATED | Renal Insufficiency, Chronic |
Nanfang Hospital, Southern Medical University |
2008-02 | |
| NCT00429364 | COMPLETED | Marfan Syndrome |
Carelon Research |
2007-01 | PHASE3 |
| NCT00763893 | TERMINATED | Marfan Syndrome |
Assistance Publique - Hôpitaux de Paris |
2008-09 | PHASE3 |
| NCT01390181 | TERMINATED | Bicuspid Aortic Valve; Thoracic Aortic Aneurysm |
University of Michigan |
2011-09 | |
| NCT01234922 | TERMINATED | Hypertension; Unspecified Adult Solid Tumor, Protocol Specific |
Wake Forest University Health Sciences |
2011-02 | PHASE2 |
| NCT00701428 | COMPLETED | Hypertension; Sleep Apnea |
Skaraborg Hospital |
2008-06 | PHASE4 |
| NCT01934569 | COMPLETED | Healthy |
Pfizer |
2013-09 | PHASE1 |
| NCT01797926 | COMPLETED | Hypertension |
GlaxoSmithKline |
2013-05-23 | PHASE1 |
| NCT00683124 | UNKNOWN | Marfan Syndrome |
Fondazione IRCCS Policlinico San Matteo di Pavia |
2008-07 | PHASE3 |
| NCT01281787 | COMPLETED | Lung Cancer; Atrial Fibrillation |
European Institute of Oncology |
2008-04 | PHASE3 |
| NCT00814255 | COMPLETED | Focal Segmental Glomerulosclerosis |
NYU Langone Health |
2008-12 | PHASE2 |
| NCT01224860 | COMPLETED | Renal Transplant |
Mario Negri Institute for Pharmacological Research |
2009-01 | PHASE2 |
| NCT01692717 | COMPLETED | Healthy Subjects |
Azidus Brasil |
2013-02-28 | PHASE1 |
| NCT01371747 | COMPLETED | Chronic Kidney Disease; Hypertension; Hyperkalemia |
Relypsa, Inc. |
2011-06 | PHASE2 |
| NCT01277822 | COMPLETED | Hypertension |
Organon and Co |
2011-05-30 | PHASE4 |
| NCT01409408 | WITHDRAWN | Hypertension; Diabetes Mellitus |
Hospital Universitario Pedro Ernesto |
2011-04 | PHASE4 |
| NCT01766050 | COMPLETED | Transplant Rejection |
Bristol-Myers Squibb |
2013-01 | PHASE4 |
| NCT01176032 | COMPLETED | Hypertension; Left Ventricle Hypertrophy |
Novartis Pharmaceuticals |
2010-06 | PHASE4 |
| NCT01858623 | COMPLETED | Healthy Normotensive Participants |
Damanhour University |
2013-02 | |
| NCT01145612 | UNKNOWN | Marfan Syndrome |
Forteza, Albert, M.D. |
2008-10 | PHASE3 |
| NCT01828359 | COMPLETED | Hypertension |
Hanmi Pharmaceutical Company Limited |
2010-08 | PHASE4 |
| NCT00723801 | COMPLETED | Marfan Syndrome |
Brigham and Women's Hospital |
2007-10 | PHASE3 |
| NCT01713647 | COMPLETED | Fasting |
Pharmaceutical Research Unit, Jordan |
2012-10 | PHASE1 |
| NCT01087749 | COMPLETED | Kidney Disease |
University of California, San Francisco |
2010-03 | PHASE1 |
| NCT01806324 | COMPLETED | Hypertension; Hyperlipidemia |
HanAll BioPharma Co., Ltd. |
2012-04 | PHASE1 |
| NCT00467831 | TERMINATED | Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease |
National Human Genome Research Institute (NHGRI) |
2007-04 | PHASE1; PHASE2 |
| NCT01648231 | COMPLETED | Hypertension |
GlaxoSmithKline |
2012-08-06 | PHASE1 |
| NCT00756938 | COMPLETED | Hypertension |
Organon and Co |
2009-03-01 | PHASE3 |
| NCT01982695 | COMPLETED | Duchenne Muscular Dystrophy (DMD); Cardiomyopathy |
Nationwide Children's Hospital |
2009-03 | |
| NCT01398423 | COMPLETED | Hypertension; Diabetes Mellitus, Type 2 |
InVasc Therapeutics, Inc. |
2011-06 | PHASE2 |
| NCT01320397 | UNKNOWN | Essential Hypertension |
RostaQuo S.p.A. |
2011-05 | PHASE2 |
| NCT00340678 | COMPLETED | Diabetic Nephropathy |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
1995-08 | PHASE3 |
| NCT01302691 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
2011-01-01 | PHASE3 |
| NCT01180413 | COMPLETED | Essential Hypertension; High Blood Pressure |
Aarhus University Hospital |
2010-12 | PHASE4 |
| NCT01529749 | COMPLETED | HIV-1 Infection |
Felipe Garcia |
2012-02 | PHASE4 |
| NCT00879879 | COMPLETED | Precancerous Condition |
University of South Florida |
2009-03 | |
| NCT00198562 | UNKNOWN | Hypertension |
Ministry of Health, Labour and Welfare, Japan |
2000-04 | PHASE4 |
| NCT01667614 | COMPLETED | Type 2 Diabetes Mellitus; Diabetic Nephropathy; Essential Hypertension |
Tehran University of Medical Sciences |
2010-05 | PHASE2 |
| NCT01307046 | COMPLETED | Hypertension |
Organon and Co |
2011-03-29 | PHASE3 |
| NCT00402194 | COMPLETED | Obesity; Insulin Resistance; Impaired Glucose Tolerance; Pre-diabetes |
Indiana University |
2005-06 | |
| NCT01305850 | UNKNOWN | Peritoneal Membrane Failure |
Chulalongkorn University |
2010-07 | PHASE4 |
| NCT01321021 | COMPLETED | Memory, Long-Term; Memory, Short-Term |
Prof. Dominique de Quervain, MD |
2011-03 | |
| NCT01324752 | COMPLETED | Drug Interaction Potentiation |
Vifor Pharma |
2011-03 | PHASE1 |
| NCT01830517 | COMPLETED | Hypertension; Stroke |
Hanmi Pharmaceutical Company Limited |
2007-08 | PHASE4 |
| NCT00067990 | COMPLETED | Kidney Disease; Proteinuria |
University of Minnesota |
2002-12 | PHASE4 |
| NCT01271374 | UNKNOWN | Hypertension |
InVasc Therapeutics, Inc. |
2010-04 | PHASE4 |
| NCT01570569 | COMPLETED | Healthy |
Inje University |
2011-01 | PHASE1 |
| NCT01857999 | COMPLETED | Congestive Heart Failure; Low Cardiac Output |
InCor Heart Institute |
2008-09 | PHASE4 |
| NCT01187862 | COMPLETED | Cytochrome; Pharmacokinetics |
University Hospital, Basel, Switzerland |
2010-07 | PHASE1 |
| NCT01198249 | COMPLETED | Essential Hypertension |
Yonsei University |
2010-09 | PHASE1 |
| NCT00651235 | UNKNOWN | Marfan Syndrome |
National Taiwan University Hospital |
2007-02 | PHASE2 |
| NCT00922311 | COMPLETED | IgA Nephropathy |
The University of Hong Kong |
2009-07 | PHASE4 |
| NCT00795847 | COMPLETED | Hypertension |
Kurume University |
2008-11 | PHASE4 |
| NCT00670787 | COMPLETED | Hypertension |
Kyushu University |
2008-06 | PHASE3 |
| NCT01197014 | COMPLETED | Healthy |
Hanmi Pharmaceutical Company Limited |
2010-09 | PHASE1 |
| NCT00593710 | COMPLETED | Marfan Syndrome |
University of British Columbia |
2008-01 | PHASE2 |
| NCT01197001 | COMPLETED | Healthy |
Hanmi Pharmaceutical Company Limited |
2010-08 | PHASE1 |
| NCT00673790 | COMPLETED | Hypertension |
Forest Laboratories |
2008-05-15 | PHASE4 |
| NCT01150461 | COMPLETED | Hypertrophic Cardiomyopathy |
Massachusetts General Hospital |
2007-02 | PHASE2 |
| NCT01041963 | UNKNOWN | Continuous Ambulatory Peritoneal Dialysis |
Chulalongkorn University |
2009-06 | PHASE4 |
| NCT00880386 | WITHDRAWN | Dyspnea; Lung Cancer; Pulmonary Complications; Radiation Fibrosis |
University of South Florida |
2009-03 | |
| NCT00456963 | TERMINATED | Diabetes Mellitus; Hypertension |
Istituto Auxologico Italiano |
2007-09 | PHASE4 |
| NCT00446563 | COMPLETED | Hypertension; Hypertrophy, Left Ventricular |
Novartis |
2007-03 | PHASE3 |
| NCT01127217 | COMPLETED | Hypertension |
Hanmi Pharmaceutical Company Limited |
2009-05 | PHASE3 |
| NCT00734630 | COMPLETED | Hypertension |
Forest Laboratories |
2008-08 | PHASE4 |
| NCT00856960 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
2010-01 | PHASE1 |
| NCT04954560 | COMPLETED | Uric Acid Concentration, Serum, Quantitative Trait Locus 7 |
Medical University of Lodz |
2008-01-01 | |
| NCT00931710 | COMPLETED | Stage 2 Systolic Hypertension |
Novartis |
2009-07 | PHASE4 |
| NCT00949884 | COMPLETED | Hypertension |
Daiichi Sankyo |
2009-08 | PHASE4 |
| NCT00981929 | TERMINATED | Cytochrome P450 Phenotype and Genotype Metrics |
University of Southern Denmark |
2009-09 | |
| NCT00388388 | TERMINATED | Pre-hypertension; Pre-diabetes |
Sir Mortimer B. Davis - Jewish General Hospital |
2007-03 | PHASE2 |
| NCT00496834 | COMPLETED | Hypertension |
Organon and Co |
2008-02-01 | PHASE4 |
| NCT00732407 | UNKNOWN | Diabetes Mellitus; Atherosclerosis |
Assaf-Harofeh Medical Center |
2008-09 | |
| NCT00732966 | UNKNOWN | Hypertension |
Assaf-Harofeh Medical Center |
2008-09 | |
| NCT00739674 | COMPLETED | Hypertension |
Organon and Co |
2008-02-01 | PHASE3 |
| NCT00699036 | UNKNOWN | Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease |
Brooke Army Medical Center |
2007-04 | PHASE2 |
| NCT00922480 | COMPLETED | Hypertension |
Boryung Pharmaceutical Co., Ltd |
2008-12 | PHASE3 |
| NCT01431508 | COMPLETED | Hypertension |
Organon and Co |
2007-08-01 | PHASE4 |
| NCT00617877 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
2005-03 | |
| NCT00754429 | COMPLETED | Ischemic Stroke |
Taipei Veterans General Hospital, Taiwan |
2004-06 | PHASE4 |
| NCT00492128 | COMPLETED | Hypertension |
Yokohama City University Medical Center |
2007-09 | PHASE4 |
| NCT00546754 | COMPLETED | Hypertension |
Organon and Co |
2007-05-01 | PHASE3 |
| NCT00090259 | COMPLETED | Heart Failure |
Organon and Co |
2001-12-19 | PHASE3 |
| NCT03912285 | COMPLETED | Healthy |
Korea University Anam Hospital |
2008-01-10 | PHASE1 |
| NCT00880386 | Withdrawn | Dyspnea|Lung Cancer|Pulmonary Complications|Radiation Fibrosis |
University of South Florida|National Cancer Institute (NCI) |
2009-03 | Not Applicable |
| NCT00716950 | UNKNOWN | Essential Hypertension |
University of Pavia |
2008-07 | PHASE4 |
| NCT00813722 | UNKNOWN | Blood Pressure |
University of Sao Paulo |
1999-03 | PHASE4 |
| NCT00940667 | COMPLETED | Hypertension |
Hanmi Pharmaceutical Company Limited |
2008-05 | PHASE3 |
| NCT00675987 | COMPLETED | Obesity; Hypertension; Hyperglycemia |
Brigham and Women's Hospital |
2007-05 | PHASE4 |
| NCT00647257 | UNKNOWN | Atrial Fibrillation |
Chung Shan Medical University |
2008-04 | |
| NCT00940680 | COMPLETED | Hypertension |
Hanmi Pharmaceutical Company Limited |
2008-04 | PHASE3 |
| NCT00568178 | COMPLETED | Proteinuria |
Organon and Co |
2007-06-01 | PHASE3 |
| NCT01033318 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
2007-09-11 | PHASE1 |
| NCT00669435 | UNKNOWN | Hypertension |
University of Pavia |
2008-04 | PHASE4 |
| NCT00659451 | UNKNOWN | Essential Hypertension; Diabetes Mellitus |
University of Pavia |
2008-04 | PHASE3 |
| NCT00284128 | COMPLETED | Hypertension |
Sanofi |
2005-12 | PHASE2; PHASE3 |
| NCT00546052 | COMPLETED | Hypertension; Metabolic Disorder |
Organon and Co |
2005-09-01 | PHASE3 |
| NCT00942344 | COMPLETED | Hypertension |
Hanmi Pharmaceutical Company Limited |
2007-05 | PHASE2 |
| NCT00219141 | COMPLETED | Hypertension; Left Ventricular Hypertrophy; Overweight |
Novartis Pharmaceuticals |
2005-10 | PHASE3 |
| NCT00447603 | TERMINATED | Hypertension |
Organon and Co |
2007-05-24 | PHASE3 |
| NCT01011062 | COMPLETED | Insulin Resistance; Type 2 Diabetes |
Institute for Clinical and Experimental Medicine |
2004-01 | |
| NCT00774904 | COMPLETED | Diabetic Nephropathy |
Xi'an Jiaotong University |
2007-04 | |
| NCT00419835 | COMPLETED | Macroalbuminuric Diabetic Nephropathy |
University of Sao Paulo |
2005-05 | PHASE4 |
| NCT00720577 | COMPLETED | Peripheral Arterial Disease |
Medtronic Endovascular |
2005-12 | EARLY_PHASE1 |
| NCT00325637 | COMPLETED | Hypertension; Stroke |
Boryung Pharmaceutical Co., Ltd |
2005-01 | PHASE3 |
| NCT00398541 | COMPLETED | Hypertension |
Organon and Co |
2005-03-01 | PHASE3 |
| NCT00354991 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
2006-06-01 | PHASE3 |
| NCT00344110 | COMPLETED | Hypertension |
Novartis |
2006-06 | PHASE3 |
| NCT00097955 | COMPLETED | Diabetic Nephropathy |
Novartis Pharmaceuticals |
2004-10 | PHASE2 |
| NCT00143949 | COMPLETED | Type 1 Diabetes |
Michael Mauer, MD |
1997-03 | PHASE2 |
| NCT00289887 | COMPLETED | Hypertension |
Organon and Co |
2006-02 | PHASE3 |
| NCT01115426 | COMPLETED | IGA Glomerulonephritis |
University Magna Graecia |
1997-01 | PHASE4 |
| NCT00943852 | COMPLETED | Hypertension |
Organon and Co |
2006-08 | PHASE1 |
| NCT00449111 | TERMINATED | Hypertension |
Organon and Co |
2006-03-13 | PHASE3 |
| NCT00400218 | COMPLETED | Hypertension |
Organon and Co |
2005-09-01 | PHASE3 |
| NCT00168857 | COMPLETED | Hypertension; Diabetic Nephropathies |
Boehringer Ingelheim |
2003-07-09 | PHASE4 |
| NCT00234858 | COMPLETED | Hypertension; Metabolic Syndrome |
Abbott |
2004-03 | PHASE4 |
| NCT00157963 | COMPLETED | Essential Hypertension |
Organon and Co |
2005-02-05 | PHASE4 |
| NCT00152633 | WITHDRAWN | Hypertension |
University of Erlangen-Nürnberg Medical School |
2005-09 | PHASE2; PHASE3 |
| NCT00155064 | COMPLETED | Hyperaldosteronism |
National Taiwan University Hospital |
2002-07 | PHASE4 |
| NCT00364988 | COMPLETED | Type 2 Diabetes; Diabetic Nephropathy |
Shanghai Jiao Tong University School of Medicine |
2005-01 | |
| NCT00151827 | COMPLETED | Essential Hypertension; Renal Impairment |
Sankyo Pharma Gmbh |
2003-08 | PHASE3 |
| NCT00307060 | COMPLETED | Mild to Severe Hypertension |
Organon and Co |
2004-12-01 | PHASE3 |
| NCT00751751 | COMPLETED | Essential Hypertension |
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
2003-06 | PHASE3 |
| NCT01102478 | COMPLETED | Hypertension |
Roxane Laboratories |
2005-02 | |
| NCT00133185 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2004-03 | PHASE3 |
| NCT01102465 | COMPLETED | Hypertension |
Roxane Laboratories |
2005-02 | |
| NCT00856271 | COMPLETED | Essential Hypertension |
Daiichi Sankyo |
2004-08 | PHASE3 |
| NCT00140907 | COMPLETED | High Blood Pressure |
Organon and Co |
2000-03-14 | PHASE4 |
| NCT01216878 | COMPLETED | Hypertension |
Roxane Laboratories |
2004-09 | |
| NCT01216852 | COMPLETED | Hypertension |
Roxane Laboratories |
2004-08 | |
| NCT00140959 | COMPLETED | Hypertension |
Organon and Co |
2003-02-01 | PHASE4 |
| NCT00953680 | COMPLETED | Hypertension |
Organon and Co |
2004-04 | PHASE1 |
| NCT03276598 | COMPLETED | Hypertension; Pharmacogenetics |
Helsinki University Central Hospital |
1999-11-25 | PHASE4 |
| NCT01149473 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2004-03 | PHASE1 |
| NCT01149486 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2004-01 | PHASE1 |
| NCT01124162 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2003-10 | PHASE1 |
| NCT01124175 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2003-10 | PHASE1 |
| NCT00857285 | COMPLETED | Essential Hypertension |
Daiichi Sankyo |
2002-05 | PHASE3 |
| NCT00274638 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2002-07 | PHASE4 |
| NCT00541684 | COMPLETED | Hypertension |
Organon and Co |
2001-07-11 | PHASE3 |
| NCT00092209 | COMPLETED | Hypertension |
Organon and Co |
2002-04 | PHASE3 |
| NCT00480805 | COMPLETED | Type 2 Diabetes Mellitus; Hypertension |
Organon and Co |
2001-08-08 | PHASE3 |
| NCT02172586 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2000-01 | PHASE4 |
| NCT00140985 | COMPLETED | Renal Disorder |
Organon and Co |
2000-02 | PHASE4 |
| NCT00338260 | COMPLETED | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) |
Organon and Co |
1995-06 | PHASE3 |
| NCT02200653 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2000-05 | PHASE4 |
| NCT00308347 | COMPLETED | Type 2 Diabetes; Nephropathy |
Organon and Co |
1996-05 | PHASE3 |
| NCT02269176 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2000-07 | PHASE3 |
| NCT02200640 | COMPLETED | Hypertension |
Boehringer Ingelheim |
2000-03 | PHASE4 |
| NCT02183701 | COMPLETED | Hypertension |
Boehringer Ingelheim |
1998-04 | PHASE3 |
| NCT00888355 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
1992-05 | PHASE3 |
| NCT00887250 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
1991-12 | PHASE3 |
| NCT00886600 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
1991-05 | PHASE3 |
| NCT00882440 | COMPLETED | Hypertension |
Merck Sharp & Dohme LLC |
1990-12 | PHASE3 |
| NCT00338091 | TERMINATED | Renal Insufficiency,Chronic; Disease Progression; Proteinuria; Dose-Response Relationship,Drug; ACE Inhibitor; Angiotensin II Type 1 Receptor Blockers |
Southern Medical University, China |
2002-01 | |
| NCT00369538 | SUSPENDED | Proteinuria; Hypertension; End Stage Renal Disease |
University Hospital, Strasbourg, France |
2006-08 | PHASE4 |
| NCT00159692 | COMPLETED | Hypertension |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2003-03 | PHASE4 |
| NCT01218724 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00663377 | COMPLETED | Heart Failure |
Tottori University Hospital |
2006-04 | PHASE4 |
| NCT00649311 | TERMINATED | Hypertension |
Pfizer |
2003-04 | PHASE2 |
| NCT00239096 | UNKNOWN | Alcoholic Liver Cirrhosis; Ascites |
Odense University Hospital |
2005-09 | PHASE4 |
| NCT00001741 | COMPLETED | Cardiovascular Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
1997-11 | PHASE1 |
| NCT01218711 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00298714 | COMPLETED | Chronic Hepatitis C; Liver Fibrosis |
Hospital Clinic of Barcelona |
2003-03 | PHASE4 |
| NCT00362960 | COMPLETED | Type 2 Diabetes Mellitus; Diabetic Nephropathy; Proteinuria; Renal Disease |
Sankyo Pharma Gmbh |
2003-05 | PHASE3 |
| NCT00381134 | COMPLETED | Diabetes; Kidney Disease; Hypertension |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2003-07 | PHASE2 |
| NCT00561704 | COMPLETED | Obese; Type 2 Diabetes; Diabetic Nephropathy; Glucose Metabolism; Angiotensin II Type 1 Receptor Blockers |
Shanghai Jiao Tong University School of Medicine |
2007-04 | |
| NCT01218698 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00160225 | COMPLETED | Hypertension |
Solvay Pharmaceuticals |
2005-07 | PHASE2 |
| NCT02238457 | WITHDRAWN | Heart Failure |
Baker Heart and Diabetes Institute |
PHASE4 | |
| NCT01218022 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00530595 | COMPLETED | Cardiovascular Disease |
Saitama Medical University |
||
| NCT00237588 | COMPLETED | Hypertension |
Ullevaal University Hospital |
2004-12 | PHASE4 |
| NCT00407862 | COMPLETED | Hypertension; Impaired Glucose Tolerance |
Medical University of Graz |
2005-01 | PHASE4 |
| NCT00565396 | UNKNOWN | Chronic Kidney Insufficiency; Angiotensin-Converting Enzyme Inhibitors; Angiotensin II Type 1 Receptor Blockers; Proteinuria |
Shanghai Municipal Health Bureau |
2004-09 | |
| NCT00533858 | UNKNOWN | Hypertension |
Seoul National University Hospital |
2007-09 | PHASE4 |
| NCT00361023 | COMPLETED | Type 2 Diabetes; Diabetic Nephropathy |
Shanghai Jiao Tong University School of Medicine |
2006-01 | |
| NCT00519870 | COMPLETED | Pulmonary Hypertension |
Baskent University |
2005-01 | PHASE3 |
| NCT00185094 | COMPLETED | Hypertension; Insulin Resistance; Metabolic Syndrome |
Daiichi Sankyo |
2004-02 | PHASE4 |
(data from https://clinicaltrials.gov, updated on 2026-04-21)
Check the
Losartan Potassium (DuP 753)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Losartan Potassium (DuP 753) Solubility in DMSO
- Losartan Potassium (DuP 753) Stock Solution
- Losartan Potassium (DuP 753) Storage
- Losartan Potassium (DuP 753) Stability
- Losartan Potassium (DuP 753) Molecular Weight
- Losartan Potassium (DuP 753) SMILES
- Losartan Potassium (DuP 753) CAS Number
- Losartan Potassium (DuP 753) Chemical Structure (2D and 3D)
- Losartan Potassium (DuP 753) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.